This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Stocks With Upgrades: DVN, HTLD, LRCX, XEC, CFN

Stocks in this article: DVN HTLD LRCX XEC CFN

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Cimarex Energy

The oil and gas exploration company reported Wednesday fourth-quarter earnings of $116.9 million, or $1.36 a share, slightly down from year-ago earnings of $117.6 million, or $1.37.

"We reiterate our Perform rating on the shares due to XEC's below-average production growth rate, estimated at 4-10% in 2012, and an oil/gas production mix that continues to be highly levered to gas. XEC does not have any gas hedges in 2012 or 2013, leaving it fully exposed to the current low gas price environment," Oppenheimer analysts wrote in a report Thursday.

Shares of Cimarex Energy were upgraded to buy from hold by TheStreet Ratings.

Cimarex has a forward P/E of 11.61; the average for exploration and production companies is 20.04. For comparison, Southwestern Energy (SWN) and Concho Resources (CXO) both have higher forward P/Es of 21.47 and 21.87, respectively.

Thirteen of the 21 analysts who cover Cimarex rated it a buy; eight rated it a hold.

Cimarex gets a B- grade from TheStreet Ratings with a $94.24 price target. The stock closed Thursday at $80.96 and has increased 30.79% year to date.


The medical technology company earlier this month reported second-quarter earnings of $95 million, or 42 cents a share, up from year-ago earnings of $76 million, or 34 cents.

"We estimate that in order to meet management's goal of 20%-plus operating margin exiting fiscal 2014, the company needs to reduce expenses by 3% from the fiscal 2011 base," Morgan Keegan analysts wrote in a report Friday. "Given the sheer number of cost reduction initiatives that are ongoing, we believe that management can meets its goals."

Shares of CareFusion were upgraded to buy from hold by TheStreet Ratings.

CareFusion has a forward P/E of 12.89; the average for medical equipment companies is 32.59. For comparison, Abiomed (ABMD) has a forward P/E of 121.79.

Of the 16 analysts who cover CareFusion, nine rated it a buy and seven rated it a hold.

TheStreet Ratings gives CareFusion a B grade with a $29.29 price target. The stock closed Thursday at $25.86 and has increased 1.77% year to date.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to:

>To follow the writer on Twitter, go to Alexandra Zendrian.

3 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs